Last reviewed · How we verify
AK112 high dose
AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses.
AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (Phase 2 evaluation).
At a glance
| Generic name | AK112 high dose |
|---|---|
| Sponsor | Akeso |
| Drug class | Bispecific checkpoint inhibitor |
| Target | PD-1 and CTLA-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AK112 functions as a bispecific monoclonal antibody designed to bind both PD-1 and CTLA-4, two key immune checkpoint molecules. By engaging both pathways simultaneously, the drug aims to provide enhanced T-cell activation and proliferation compared to single-checkpoint inhibitors, potentially overcoming resistance mechanisms in cancer immunotherapy.
Approved indications
- Advanced or metastatic solid tumors (Phase 2 evaluation)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Diarrhea
- Rash
Key clinical trials
- A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer With Acquired Resistance to Immunotherapy and High YAP Protein Expression (PHASE2)
- Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE2)
- Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer (PHASE2)
- A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk (PHASE4)
- Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer (PHASE2)
- A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK112 high dose CI brief — competitive landscape report
- AK112 high dose updates RSS · CI watch RSS
- Akeso portfolio CI